Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of lipo-prostaglandin E1 （lipo-PGE1) on
renal oxygenation in patients with diabetic nephropathy by blood oxygenation level dependent
magnetic resonance imaging (BOLD-MRI).patients with stable chronic kidney disease (CKD) were
included. All patients were divided into two groups: diabetic nephropathy（DN) and CKD without
diabetes. In addition to the conventional treatments, all patients received 10 ug lipo-PGE1
intravenously once daily for consecutive 14 days. Kidney BOLD-MRI were performed before and
after lipo-PGE1 administration to acquire bilateral renal cortical R2*(CR2*) and medullary
R2* (MR2*) values. Meanwhile, the clinical indexes at baseline and under lipo-PGE1 including
24 hours urinary protein and serum creatinine were collected. the investigators want to prove
Lipo-PGE1 can improve kidney medullary oxygenation in patients with DN.